Lipids
Phase 2 RCT | Small interfering RNA to reduce Lipoprotein(a) in cardiovascular disease.
8 Nov, 2022 | 12:30h | UTCSmall Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Lipoprotein(a) is similar to LDL cholesterol but contains apolipoprotein(a). A trial tested the effects of an oligonucleotide drug targeting apo(a) mRNA on lipoprotein(a) concentrations in patients with CVD. #AHA22 https://t.co/eLgnrnTm5D pic.twitter.com/QmNUcxeJwX
— NEJM (@NEJM) November 6, 2022
RCT | Triglyceride lowering with Pemafibrate fails to reduce CVD risk in patients with Type 2 DM and hypertriglyceridemia.
7 Nov, 2022 | 12:54h | UTCTriglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk – New England Journal of Medicine (link to abstract – $ for full-text)
News Releases:
Commentaries:
Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT – TCTMD
Commentary on Twitter
In a randomized trial, the incidence of cardiovascular events was not lower in patients with diabetes, HTG, and low HDL cholesterol levels who received pemafibrate, although TG, VLDL cholesterol, remnant cholesterol, and Apo C-III levels decreased. #AHA22 https://t.co/bNtIAwWTX0 pic.twitter.com/yWaTWarlsv
— NEJM (@NEJM) November 5, 2022
Guidance for the diagnosis and treatment of hypolipidemia disorders.
28 Oct, 2022 | 13:19h | UTCGuidance for the diagnosis and treatment of hypolipidemia disorders – Journal of Clinical Lipidology
Cohort Study | Associations of hypertriglyceridemia onset age with cardiovascular disease and all‐cause mortality in adults.
20 Oct, 2022 | 12:25h | UTC
Cross-sectional study | Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease.
20 Oct, 2022 | 12:22h | UTC
Commentary on Twitter
The Lp(a) Heritage study, in prep for Lp(a) HORIZON, is now out- 48,129 pts eligible otherwise for Lp(a) HORIZON, with survey of Lp(a) levels. Data shows a higher prevalence of ⏫levels in pts with ASCVD vs general population at >70 mg/dL/>150 nmol/L https://t.co/lcp0gSLhCJ pic.twitter.com/DBGBNk0SOa
— Sam Tsimikas, MD (@Lpa_Doc) October 18, 2022
Under a http://creativecommons.org/licenses/by-nc/4.0/ license
RCT | Combination of pitavastatin and ezetimibe vs. monotherapy of pitavastatin in patients with primary hypercholesterolemia.
19 Oct, 2022 | 14:15h | UTC
Perspective | The polypill: from concept and evidence to implementation.
18 Oct, 2022 | 12:55h | UTCThe polypill: from concept and evidence to implementation – The Lancet (free registration required)
Related:
Opinion: A new important study supports wider use of the polypill
Perspective: Are Polypills and Population-based Treatment the Next Big Things?
The Polypill Revisited: Why We Still Need Population-Based Approaches in the Precision Medicine Era
Randomized Trial: Polypill for Cardiovascular Disease Prevention in an Underserved Population
Perspective: The Polypill and the Long Journey to Major Impact
Research: Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care
Calculator | Estimating individual lifetime risk of cardiovascular events in adults with type 2 diabetes.
11 Oct, 2022 | 13:29h | UTCSee also: DIAL Model Calculator
Cohort Study | Association between dairy intake and risk of CV disease and mortality in patients with stable angina pectoris.
28 Sep, 2022 | 13:38h | UTC
Network M-A | Associations between statins and adverse events in secondary prevention of cardiovascular disease.
20 Sep, 2022 | 13:30h | UTC
Network M-A | Comparative efficacy of lipid‐lowering therapies added to maximally tolerated statins for the reduction of LDL cholesterol.
11 Sep, 2022 | 22:38h | UTC
2022 ACC Expert Consensus | Role of nonstatin therapies for LDL-cholesterol lowering and managing cardiovascular disease risk.
2 Sep, 2022 | 13:17h | UTCNews Release: ACC Issues Guidance to Address New Nonstatin Therapies – American College of Cardiology
Commentary: New on the Scene Nonstatin Drugs: Experts Provide Guidance – TCTMD
Commentary on Twitter
📢 ACC releases Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk
Read more: https://t.co/WDOSPgQ1bx #ACCClinicalDoc pic.twitter.com/nt8S2pdBgD
— American College of Cardiology (@ACCinTouch) August 25, 2022
#ESCCongress | Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomized, double-blind trials.
30 Aug, 2022 | 12:16h | UTCNews Release: Cardiovascular protection from statins greatly outweighs the risk of muscle symptoms – European Society of Cardiology
Commentary: Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration – TCTMD
Consensus Statement | Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis.
30 Aug, 2022 | 12:10h | UTC
Commentary on Twitter
Lipoprotein(a) in atherosclerotic CV and aortic stenosis – a European Atherosclerosis Society consensus statement https://t.co/Bzzpd3Bx8M
#EHJ #ESCCongress #ESCYoung @escardio @ehj_ed @rladeiraslopes pic.twitter.com/ZcqaPe581K
— European Society of Cardiology Journals (@ESC_Journals) August 29, 2022
#ESCCongress | Study shows long-term Evolocumab appears to be safe in patients with established atherosclerotic cardiovascular disease.
30 Aug, 2022 | 12:12h | UTCNews Release: Long-term evolocumab therapy leads to further reductions in cardiovascular events – European Society of Cardiology
Original Article: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease – New England Journal of Medicine
Commentary on Twitter
#OriginalResearch SimPub #ESCCongress: In this open-label extension of #FOURIER RCT, long-term evolocumab therapy for >8 yrs was associated w/ persistently low rates and greater reduction in MACE compared w/ delayed treatment initiation among patients w… https://t.co/9g97s4MZSt pic.twitter.com/y5uN53gdKo
— Circulation (@CircAHA) August 29, 2022
USPSTF Recommendation Statement | Statin use for the primary prevention of cardiovascular disease in adults.
24 Aug, 2022 | 14:21h | UTCEditorials:
Author Interview: USPSTF Recommendation: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults – JAMA
Patient Page: Statins for the Prevention of Cardiovascular Disease – JAMA
Commentary: Latest statins guidance keeps more conservative approach to preventing first stroke or heart attack – CNN
Position Paper | Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients.
16 Aug, 2022 | 13:42h | UTC
Clinical Practice Update | The detection, evaluation, and management of dyslipidemia in children and adolescents.
15 Aug, 2022 | 12:12h | UTC
Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function.
12 Aug, 2022 | 15:11h | UTCCommentaries:
Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution – TCTMD
In a cohort study with a median follow‐up of 23.2 years, both very low and very high LDL‐C levels are associated with increased risk of cardiovascular mortality in the general population.
4 Aug, 2022 | 14:25h | UTC
Position Paper | Red yeast rice for dyslipidemias and cardiovascular risk reduction.
29 Jul, 2022 | 12:35h | UTC
Consensus statement on the management of familial hypercholesterolemia.
28 Jul, 2022 | 13:16h | UTC
Chasing LDL cholesterol to the bottom — PCSK9 in perspective.
22 Jul, 2022 | 11:36h | UTCChasing LDL cholesterol to the bottom — PCSK9 in perspective – Nature Cardiovascular Research (if the link is paywalled, try this one)
Commentary on Twitter
Review| @LaleTokgozoglu and Peter Libby discuss the management of #atherogenic #LDL cholesterol with an emphasis on the role #PCSK9 inhibition strategies https://t.co/k1wPKAdotU
— Nature Cardiovascular Research (@NatureCVR) June 17, 2022
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
21 Jul, 2022 | 13:11h | UTC
Open-label RCT | Moderate-intensity statin plus ezetimibe is noninferior to high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease.
20 Jul, 2022 | 12:32h | UTCLong-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial – The Lancet (link to abstract – $ for full-text)